Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Bevacizumab And Near Infrared Probe Conjugated Iron Oxide Nanoparticles For Vascular Endothelial Growth Factor Targeted MR And Optical Imaging.

Run Lin, Jing Huang, L. Wang, Yuancheng Li, M. Lipowska, H. Wu, J. Yang, Hui Mao
Published 2018 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Vascular endothelial growth factor (VEGF) plays a pivotal role in the cascade of development and progression of cancers. Targeting this cancer hallmark is a logical strategy for imaging based cancer detection and monitoring the anti-angiogenesis treatment. Using Bevacizumab (Avastin®), which is a recombinant humanized monoclonal antibody directly against VEGF and an angiogenesis inhibitor, as a targeting ligand, a multimodal VEGF targeted molecular imaging probe was developed by conjugating near infrared dye (NIR830) labeled bevacizumab to magnetic iron oxide nanoparticles (IONP) for optical and magnetic resonance (MR) imaging of cancers over-expressing VEGF. The targeting effect of NIR830-bevacizumab-IONPs on VEGF over-expressing cells was investigated by receptor mediated cell uptake experiments and a blocking assay using VEGF over-expressing 4T1 breast cancer cells. Systemic administration of VEGF-targeted NIR830-bevacizumab-IONPs into mice bearing 4T1 breast tumors resulted in higher accumulation of targeting IONPs in tumors compared to non-targeted IONPs. Quantitative analysis of T2-weighted MRI at 48 h post-injection revealed that the averaged percentage of signal intensity change in tumors treated with NIR830-bevacizumab-IONPs was 52.4 ± 11.0% compared to 26.9 ± 12.4% in controls treated with non-targeted IONPs. The results demonstrated the feasibility and efficacy of NIR830-bevacizumab-IONPs as a VEGF targeting dual-modality molecular imaging probe that can be potentially used for imaging of cancers with VEGF over-expression and delivery of bevacizumab for imaging guided anti-cancer treatment.
This paper references
Page 10 Biomater Sci. Author manuscript; available in PMC 2019 May 29. A uhor M anscript A uhor M anscript A uhor M anscript A uhor M
G Zalcman (2016)
10.1016/S1470-2045(14)70381-X
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
T. Seto (2014)
10.1038/nrclinonc.2014.134
Quantitative multimodality imaging in cancer research and therapy
T. Yankeelov (2014)
10.1200/JCO.2013.51.4489
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
E. Pujade-Lauraine (2014)
Biomater Sci. Author manuscript; available in PMC 2019 May 29. A uhor M anscript A uhor M anscript A uhor M anscript A uhor M
G Zalcman (2016)
10.1039/c6bm00262e
Magnetic and fluorescent carbon-based nanohybrids for multi-modal imaging and magnetic field/NIR light responsive drug carriers.
H. Wang (2016)
10.1080/09205063.2015.1080900
Synthesis of dual-functional targeting probes for cancer theranostics based on iron oxide nanoparticles coated by centipede-like polymer connected with pH-responsive anticancer drug
H. Zhao (2015)
10.1038/nrc3236
Antibody therapy of cancer
Andrew M. Scott (2012)
10.1016/j.jconrel.2014.07.059
Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy.
N. Schleich (2014)
10.1016/j.biomaterials.2012.11.056
Magnetic, fluorescent, and thermo-responsive Fe(3)O(4)/rare earth incorporated poly(St-NIPAM) core-shell colloidal nanoparticles in multimodal optical/magnetic resonance imaging probes.
Haie Zhu (2013)
10.1016/j.biomaterials.2013.09.035
Self-assembled magnetic fluorescent polymeric micelles for magnetic resonance and optical imaging.
K. Yan (2014)
10.1016/S0140-6736(07)61904-7
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
B. Escudier (2008)
10.1210/ER.2003-0027
Vascular endothelial growth factor: basic science and clinical progress.
N. Ferrara (2004)
10.1177/0885328212437883
A dual-modal magnetic nanoparticle probe for preoperative and intraoperative mapping of sentinel lymph nodes by magnetic resonance and near infrared fluorescence imaging
Zhengyang Zhou (2013)
10.1038/nm1522
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
M. Backer (2007)
10.1056/NEJMoa1403108
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
F. Loupakis (2014)
10.1021/mp500460g
Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.
S. Heskamp (2014)
10.1016/j.jconrel.2012.04.009
Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery".
E. Mahon (2012)
10.1016/j.colsurfb.2015.10.013
Self-assembled mPEG-PCL-g-PEI micelles for multifunctional nanoprobes of doxorubicin delivery and magnetic resonance imaging and optical imaging.
Q. Guo (2015)
10.1056/NEJMoa1309748
Improved survival with bevacizumab in advanced cervical cancer.
K. Tewari (2014)
10.2147/IJN.S32154
In vivo tumor targeting and imaging with anti-vascular endothelial growth factor antibody-conjugated dextran-coated iron oxide nanoparticles
Wan-Ju Hsieh (2012)
10.3322/caac.21262
Global cancer statistics, 2012
L. Torre (2015)
10.1007/s10456-011-9249-6
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
N. Papadopoulos (2011)
10.1038/nrc1041
Early detection: The case for early detection
Ruth Etzioni (2003)
10.1016/j.jconrel.2010.08.027
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery.
F. Danhier (2010)
10.1016/j.addr.2013.09.007
Molecular imaging for cancer diagnosis and surgery.
T. Hussain (2014)
10.2967/jnumed.107.041301
In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft
W. Nagengast (2007)
10.1053/j.semnuclmed.2009.03.001
Multimodality imaging: beyond PET/CT and SPECT/CT.
S. Cherry (2009)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1016/j.addr.2012.10.002
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
H. Maeda (2013)
10.1016/j.colsurfb.2016.04.014
Facile preparation of multifunctional uniform magnetic microspheres for T1-T2 dual modal magnetic resonance and optical imaging.
L. Zhang (2016)
10.1039/c2cs15260f
The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy.
T. Doane (2012)
10.1038/nrc.2016.108
Cancer nanomedicine: progress, challenges and opportunities
J. Shi (2017)
10.3322/caac.21199
Nanooncology: The future of cancer diagnosis and therapy
A. Thakor (2013)
10.1056/NEJMOA032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
H. Hurwitz (2004)
10.1016/j.jhep.2016.07.009
Liver sinusoidal endothelial cells: Physiology and role in liver diseases.
J. Poisson (2017)
10.1039/c4cs00201f
Towards polymetallic lanthanide complexes as dual contrast agents for magnetic resonance and optical imaging.
E. Debroye (2014)
10.1021/am400713j
Casein-coated iron oxide nanoparticles for high MRI contrast enhancement and efficient cell targeting.
J. Huang (2013)
10.1038/nrc3627
VEGF targets the tumour cell
H. L. Goel (2013)
10.1038/nrc2403
VEGF-targeted therapy: mechanisms of anti-tumour activity
L. Ellis (2008)
10.1021/acs.chemrev.5b00116
Clinical Translation of Nanomedicine.
Y. Min (2015)
10.7150/thno.3623
Imaging Key Biomarkers of Tumor Angiogenesis
M. Backer (2012)
10.1016/j.addr.2014.07.009
Targeted multimodal imaging modalities.
S. Y. Lee (2014)
10.1002/JHET.5570400527
Synthesis of water-soluble near-infrared cyanine dyes functionalized with [(succinimido)oxy]carbonyl group
L. Strekowski, (2003)
10.1039/b821903f
'Two is better than one'--probes for dual-modality molecular imaging.
Lucy E. Jennings (2009)
10.1016/j.addr.2013.11.009
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
N. Bertrand (2014)
10.1038/nrd.2015.17
Ten years of anti-vascular endothelial growth factor therapy
N. Ferrara (2016)
10.1002/hep.27376
Liver sinusoidal endothelial cells in hepatic fibrosis
L. DeLeve (2015)
10.1016/j.jconrel.2012.04.038
Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.
H. Maeda (2012)
10.1148/radiol.13121038
PET/MR imaging: technical aspects and potential clinical applications.
D. Torigian (2013)
10.1186/s13075-014-0427-y
Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis
T. Nagai (2014)
10.1007/s00259-014-2702-1
Longitudinal monitoring of tumor antiangiogenic therapy with near-infrared fluorophore-labeled agents targeted to integrin αvβ3 and vascular endothelial growth factor
Xianlei Sun (2014)
10.1126/science.1125949
Molecular Imaging in Cancer
R. Weissleder (2006)
10.1021/acs.molpharmaceut.6b01033
Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.
J. Wang (2017)
10.1021/JP8029083
Reexamining the Effects of Particle Size and Surface Chemistry on the Magnetic Properties of Iron Oxide Nanocrystals: New Insights into Spin Disorder and Proton Relaxivity
Hongwei Duan (2008)
10.1016/j.addr.2010.04.009
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
J. Fang (2011)



This paper is referenced by
10.1016/j.colsurfb.2018.10.045
Dendrimer based theranostic nanostructures for combined chemo- and photothermal therapy of liver cancer cells in vitro.
Artur Jędrzak (2019)
10.3389/fchem.2018.00224
A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis
C. Tsoukalas (2018)
10.1021/acs.molpharmaceut.6b01033
Ultrasound Molecular Imaging of Angiogenesis Using Vascular Endothelial Growth Factor-Conjugated Microbubbles.
J. Wang (2017)
10.7150/thno.38261
Advances in nanomedicine for cancer starvation therapy
Shuangjiang Yu (2019)
10.3390/ijms20010095
Iron Metabolism in Cancer
Yafang Wang (2018)
10.3390/ijms21176018
Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
A. Juan (2020)
10.1016/j.semcancer.2019.07.005
Horizons of nanotechnology applications in female specific cancers.
B. Rajitha (2019)
10.3389/978-2-88945-598-0
The Chemistry of Imaging Probes
Lorenzo Tei (2018)
10.1007/s10967-020-07202-9
Synthesis of 99mTc-p-SCN-Bzl-TCMC-bevacizumab for vascular endothelial growth factor (VEGF) receptor imaging using ovarian cancer model
Bibi Faiza (2020)
10.21147/j.issn.1000-9604.2019.04.03
An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
X. Liang (2019)
10.1016/j.drudis.2020.09.031
Recent advances in targeted nanomedicine as promising antitumor therapeutics.
Siddhanth Hejmady (2020)
10.1039/d0bm00761g
Recent advances in improving tumor-targeted delivery of imaging nanoprobes.
Qianyi Zhang (2020)
10.1016/j.actbio.2019.11.027
Targeting Strategies for SuperParamagnetic Iron Oxide Nanoparticles in Cancer Therapy.
Defu Zhi (2019)
10.1007/s11307-018-1239-2
Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation
Madeline T Olson (2018)
10.3390/nano10091816
Tailoring Iron Oxide Nanoparticles for Efficient Cellular Internalization and Endosomal Escape
Laura Rueda-Gensini (2020)
Semantic Scholar Logo Some data provided by SemanticScholar